AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35087097 — intervention group
Group type: COMPARATOR
Intervention: Older participants (older than 60)
Number of subjects: 60
Study 35087332 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose perioperative corticosteroids
Number of subjects: 0
Study 35087595 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-clearing Traditional Chinese Medicine (TCM) individualized decoction
Number of subjects: 21
Study 35087595 — intervention group
Group type: COMPARATOR
Intervention: Control (individualized decoction without heat-clearing drugs)
Number of subjects: 21
Study 35087696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist/CHW teams
Number of subjects: 0
Study 35087696 — intervention group
Group type: COMPARATOR
Intervention: Community health workers (CHWs)
Number of subjects: 0
Study 35087753 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric Modulated Arc Therapy (VMAT)
Number of subjects: 155
Study 35087753 — intervention group
Group type: COMPARATOR
Intervention: Helical Tomotherapy (HT)
Number of subjects: 155
Study 35087875 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HFpEF and AF
Number of subjects: 0
Study 35087875 — intervention group
Group type: COMPARATOR
Intervention: Patients with HFpEF without AF
Number of subjects: 0
Study 35087876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Cross Prefenestration
Number of subjects: 0
Study 35088348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab (60 mg loading dose at baseline, followed by 30 mg every 4 weeks until week 12) with background topical corticosteroids or calcineurin inhibitors.
Number of subjects: 20
Study 35088348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab treatment.
Number of subjects: 20
Study 35088709 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) diagnosed in patients with apnea-hypopnea index >5 events/h
Number of subjects: 130
Study 35088709 — intervention group
Group type: COMPARATOR
Intervention: No obstructive sleep apnea (control group)
Number of subjects: 130
Study 35088733 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (DBS) at contacts closest to the dorsolateral STN
Number of subjects: 8
Study 35088733 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (DBS) at contacts closest to the SNr
Number of subjects: 8
Study 35088732 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) + Peripheral Nerve Field Stimulation (PNFS)
Number of subjects: 75
Study 35088732 — intervention group
Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 75
Study 35088735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring with evoked compound action potentials (ECAP) and late response (LR) recording
Number of subjects: 7
Study 35088930 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian 3D convolutional neural network with U-Net architecture
Number of subjects: 432
Study 35088930 — intervention group
Group type: COMPARATOR
Intervention: Established state-of-the-art techniques (BIANCA and DeepMedic)
Number of subjects: 432
Study 35089154 — intervention group
Group type: EXPERIMENTAL
Intervention: Warna-Warni Waktu intervention (six 5-minute videos with interactive activities delivered over 6 days)
Number of subjects: 1800
Study 35089154 — intervention group
Group type: EXPERIMENTAL
Intervention: Warna-Warni Waktu intervention
Number of subjects: 1800
Study 35089154 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 1800
Study 35089156 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated and individually tailored feedback letters (CO)
Number of subjects: 961
Study 35089156 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling by research staff trained in motivational interviewing (PE)
Number of subjects: 961
Study 35089156 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 961
Study 35089449 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Pill System (DPS) for measuring PrEP adherence
Number of subjects: 15
Study 35089599 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IPC and pharmacological prophylaxis
Number of subjects: 14931
Study 35089599 — intervention group
Group type: COMPARATOR
Intervention: IPC
Number of subjects: 14931
Study 35089671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
Number of subjects: 0
Study 35089671 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Polivy) added to rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP)
Number of subjects: 0
Study 35089671 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study 35089806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) on Holter
Number of subjects: 115
Study 35089806 — intervention group
Group type: EXPERIMENTAL
Intervention: VT inducibility during electrophysiology study
Number of subjects: 115
Study 35089806 — intervention group
Group type: EXPERIMENTAL
Intervention: NSVT and VT inducibility
Number of subjects: 115
Study 35089806 — intervention group
Group type: COMPARATOR
Intervention: LGE on CMR
Number of subjects: 115
Study 35089806 — intervention group
Group type: COMPARATOR
Intervention: NSVT characteristics
Number of subjects: 115
Study 35089812 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine and cisplatin (GC) plus atezolizumab (A)
Number of subjects: 39
Study 35090035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous contrast agent administration
Number of subjects: 0
Study 35090035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial contrast agent administration
Number of subjects: 0
Study 35090169 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 127
Study 35090169 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 127
Study 35090175 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan gel
Number of subjects: 255
Study 35090175 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 255
Study 35090560 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical assistance (TA) visits by PPP program staff
Number of subjects: 39
Study 35090560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitizing and educating facility staff about PrEP
Number of subjects: 39
Study 35090560 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishing formal and informal feedback and accountability mechanisms
Number of subjects: 39
Study 35090560 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering facility staff to address implementation challenges
Number of subjects: 39
Study 35090560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineffective recruitment and referral of sero-different couples
Number of subjects: 39
Study 35090560 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockouts of laboratory resources and testing supplies
Number of subjects: 39
Study 35090577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician Notification (CN)
Number of subjects: 50
Study 35090577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician Notification with Nurse Facilitation (CN+NF)
Number of subjects: 50
Study 35090577 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation Guide
Number of subjects: 50
Study 35090577 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 50
Study 35091395 — intervention group
Group type: EXPERIMENTAL
Intervention: ScanNav AI device
Number of subjects: 30
Study 35091395 — intervention group
Group type: COMPARATOR
Intervention: Control (no AI device)
Number of subjects: 30
Study 35091441 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 308
Study 35091443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 1 (prior radiotherapy/ALKi-pretreated)
Number of subjects: 156
Study 35091443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 2 (no radiotherapy/ALKi-pretreated)
Number of subjects: 156
Study 35091443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 3 (prior radiotherapy/ALKi-naïve)
Number of subjects: 156
Study 35091443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 4 (no radiotherapy/ALKi-naïve)
Number of subjects: 156
Study 35091443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (fasted condition) in arm 5 (patients with leptomeningeal carcinomatosis)
Number of subjects: 156
Study 35091442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 45
Study 35091448 — intervention group
Group type: EXPERIMENTAL
Intervention: eHsp90α
Number of subjects: 103
Study 35091448 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of eHsp90α
Number of subjects: 103
Study 35091448 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cell-conditioned medium and recombinant human Hsp90α
Number of subjects: 103
Study 35091445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg plus cetuximab-radiotherapy
Number of subjects: 18
Study 35091445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus cetuximab-radiotherapy
Number of subjects: 18
Study 35091445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus cetuximab-radiotherapy
Number of subjects: 18
Study 35091462 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis
Number of subjects: 589
Study 35091462 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 589
Study 35091462 — intervention group
Group type: COMPARATOR
Intervention: Biological disease-modifying drugs
Number of subjects: 589
Study 35091462 — intervention group
Group type: COMPARATOR
Intervention: Disease activity (ASDAS-CRP)
Number of subjects: 589
Study 35091462 — intervention group
Group type: COMPARATOR
Intervention: Functional capacity (HAQ-AS)
Number of subjects: 589
Study 35091462 — intervention group
Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 589
Study 35091465 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve lesion length measured on MRI at the acute phase of ON
Number of subjects: 51
Study 35091465 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve DIR hypersignal lesion length
Number of subjects: 51
Study 35091465 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular ganglion cell-inner plexiform layer (GCIPL) volume measured on OCT
Number of subjects: 51
Study 35091465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-contrast monocular visual acuity (LCMVA)
Number of subjects: 51
Study 35091711 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg once-daily for 12 weeks
Number of subjects: 30
Study 35091747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma DHPPA concentration in NAFLD patients
Number of subjects: 1880
Study 35091747 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing tertiles of plasma DHPPA
Number of subjects: 1880
Study 35092056 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35092110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 35092110 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35092128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM)
Number of subjects: 60
Study 35092128 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cells (PBSC)
Number of subjects: 60
Study 35092506 — intervention group
Group type: EXPERIMENTAL
Intervention: Balstilimab (AGEN2034)
Number of subjects: 0
Study 35092506 — intervention group
Group type: EXPERIMENTAL
Intervention: Balstilimab plus zalifrelimab (AGEN1884)
Number of subjects: 0
Study 35092506 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (not specified)
Number of subjects: 0
Study 35092583 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 986 200 mg
Number of subjects: 6
Study 35093104 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit-and-feedback intervention including reports on antibiotic harms, stakeholder engagement, patient and provider education, identification of local champions, and blended facilitation.
Number of subjects: 0
Study 35093104 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit-and-feedback intervention
Number of subjects: 0
Study 35093104 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 0
Study 35093126 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the cochlea
Number of subjects: 22
Study 35093147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) for fetuses with LSDs
Number of subjects: 181
Study 35093147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal gene therapy trial
Number of subjects: 181
Study 35093147 — intervention group
Group type: COMPARATOR
Intervention: Postnatal ERT
Number of subjects: 181
Study 35093147 — intervention group
Group type: COMPARATOR
Intervention: Using clinicaltrials.gov as a main source of information
Number of subjects: 181
Study 35093163 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) administered once daily for 12 weeks.
Number of subjects: 6
Study 35093164 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine (XRB)
Number of subjects: 16
Study 35093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical success (VARC-3 criteria)
Number of subjects: 1624
Study 35093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical failure (VARC-3 criteria)
Number of subjects: 1624
Study 35093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical failure
Number of subjects: 1624
Study 35093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac technical failure
Number of subjects: 1624
Study 35093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular technical failure
Number of subjects: 1624
Study 35093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical failure (periprocedural period 0-30 days)
Number of subjects: 1624
Study 35093281 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical failure (30-360 days)
Number of subjects: 1624
Study 35093737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor physiotherapy treatment (12 weekly sessions)
Number of subjects: 31
Study 35093737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pelvic floor physiotherapy treatment
Number of subjects: 31
Study 35093981 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential, phone-based text message intervention promoting HIV testing
Number of subjects: 145
Study 35093998 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted congenital CMV screening with saliva sample for CMV PCR testing
Number of subjects: 236
Study 35093998 — intervention group
Group type: EXPERIMENTAL
Intervention: Otorhinolaryngologist assessment
Number of subjects: 236
Study 35093998 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir treatment
Number of subjects: 236
Study 35094066 — intervention group
Group type: COMPARATOR
Intervention: TKI only
Number of subjects: 133
Study 35094066 — intervention group
Group type: EXPERIMENTAL
Intervention: TKI with RT (25-40 Gy in 5 fractions)
Number of subjects: 133
Study 35094747 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stent grafting
Number of subjects: 886
Study 35094747 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical replacement
Number of subjects: 886
Study 35094747 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 886
Study 35094747 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 886
Study 35094896 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm3 test with MRI and PSA ≥2 ng/ml
Number of subjects: 0
Study 35094896 — intervention group
Group type: COMPARATOR
Intervention: PSA alone
Number of subjects: 0
Study 35094896 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 35095477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 0
Study 35095477 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study 35095783 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (specific strains not mentioned)
Number of subjects: 0
Study 35095867 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with neoadjuvant chemotherapy
Number of subjects: 36
Study 35096167 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior turbinate reduction during rhinoplasty
Number of subjects: 0
Study 35096167 — intervention group
Group type: COMPARATOR
Intervention: Control group (rhinoplasty without inferior turbinate reduction)
Number of subjects: 0
Study 35096250 — intervention group
Group type: EXPERIMENTAL
Intervention: DFD-29 40mg
Number of subjects: 205
Study 35096250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 35096250 — intervention group
Group type: COMPARATOR
Intervention: DFD-29 20mg
Number of subjects: 205
Study 35096250 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 40mg
Number of subjects: 205
Study 35096584 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT)
Number of subjects: 114
Study 35096709 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding with protein-rich foods
Number of subjects: 0
Study 35096709 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35097222 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin and cefixime combination
Number of subjects: 0
Study 35097222 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 0
Study 35098120 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational dance intervention (met twice weekly for 60 min for 8 weeks)
Number of subjects: 10
Study 35098120 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 10
Study 35098120 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational dance intervention
Number of subjects: 10
Study 35098170 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT)
Number of subjects: 581
Study 35098170 — intervention group
Group type: COMPARATOR
Intervention: Placebos plus ADT
Number of subjects: 581
Study 35098333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib treatment (neurotoxic drug)
Number of subjects: 66
Study 35098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (administered every 3 weeks, maximum of six doses) plus autologous expanded NK cells (infused the day after cetuximab administration)
Number of subjects: 7
Study 35098345 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells expanded from peripheral blood mononucleated cells
Number of subjects: 7
Study 35098345 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 7
Study 35098345 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells with high ADCC potential
Number of subjects: 7
Study 35098347 — intervention group
Group type: EXPERIMENTAL
Intervention: Early breast cancer survivors (EBCS)
Number of subjects: 33
Study 35098347 — intervention group
Group type: COMPARATOR
Intervention: Inactive controls (CON)
Number of subjects: 33
Study 35098347 — intervention group
Group type: EXPERIMENTAL
Intervention: EBCS
Number of subjects: 33
Study 35098818 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 0
Study 35098818 — intervention group
Group type: COMPARATOR
Intervention: Preventive anticoagulation
Number of subjects: 0
Study 35099278 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop, an Open-Source Automated Insulin Delivery System
Number of subjects: 0
Study 35099394 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based prognostication models incorporating clinical events and time-to-event information
Number of subjects: 1432
Study 35099394 — intervention group
Group type: COMPARATOR
Intervention: Baseline models using admission variables only
Number of subjects: 1432
Study 35099394 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICU prediction models (SOFA score)
Number of subjects: 1432
Study 35099394 — intervention group
Group type: EXPERIMENTAL
Intervention: Final models incorporating clinical events and time-to-event information
Number of subjects: 1432
Study 35099638 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisegment reconstruction (MSR)
Number of subjects: 134
Study 35099638 — intervention group
Group type: COMPARATOR
Intervention: Halfscan reconstruction (HSR)
Number of subjects: 134
Study 35099638 — intervention group
Group type: EXPERIMENTAL
Intervention: MSR
Number of subjects: 134
Study 35099638 — intervention group
Group type: COMPARATOR
Intervention: HSR
Number of subjects: 134
Study 35099678 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 35099678 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib or gefitinib
Number of subjects: 0
Study 35099783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Concerns Inventory (PCI) intervention
Number of subjects: 191
Study 35099783 — intervention group
Group type: COMPARATOR
Intervention: Non-PCI treatment pathway (control)
Number of subjects: 191
Study 35100081 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications for opioid use disorder
Number of subjects: 0
Study 35100097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity drinking intervention, details not available
Number of subjects: 0
Study 35100097 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 35100339 — intervention group
Group type: EXPERIMENTAL
Intervention: Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and WT1 mRNA, 9 × 10^6 cells, administered as a priming immunization plus 2 boosters at 12, 30, and 90 days after ASCT.
Number of subjects: 20
Study 35100339 — intervention group
Group type: EXPERIMENTAL
Intervention: Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and WT1 mRNA.
Number of subjects: 20